Rights and permissions
About this article
Cite this article
Rituximab + CHOP worth it for DLBCL in The Netherlands. Pharmacoecon. Outcomes News 478, 7 (2005). https://doi.org/10.2165/00151234-200504780-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504780-00016